A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (BUILD UC)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs F8 IL10 (Primary) ; Infliximab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 25 Sep 2017 Planned End Date changed from 26 Sep 2019 to 24 Mar 2020.
- 25 Sep 2017 Planned primary completion date changed from 26 Sep 2019 to 24 Mar 2020.
- 04 Sep 2017 New trial record